Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
Biomea Fusion (Nasdaq: BMEA) recently announced the dosing of its first patient with chronic lymphocytic leukemia (CLL) in the COVALENT-101 trial, evaluating the investigational covalent menin inhibitor BMF-219. This expanded trial aims to address the high unmet need in relapsed/refractory CLL patients. Preclinical data showed BMF-219's potent cell lethality across various CLL models, demonstrating nearly 100% efficacy even against samples resistant to standard treatments. CEO Thomas Butler emphasized the potential of BMF-219 as a transformative therapy for CLL.
Biomea Fusion has received FDA clearance for its Investigational New Drug (IND) application for BMF-219, a covalent menin inhibitor targeting KRAS solid tumors. The company will initiate a Phase I/Ib clinical trial (COVALENT-102) for patients with unresectable NSCLC, CRC, and PDAC bearing KRAS mutations. This trial expands BMF-219's scope, which also includes a Phase I trial in blood cancers. BMF-219 is notable as the first menin inhibitor entering solid tumor trials, with preclinical studies demonstrating strong anti-cancer activity against various KRAS mutations.
Biomea Fusion (Nasdaq: BMEA) reported promising findings for its diabetes treatment BMF-219 at the EASD Annual Meeting, showcasing its capability to enhance pancreatic beta cell mass and function in preclinical models. In rat studies, BMF-219 exhibited significant improvements in insulin sensitivity, glycemic control, and sustained beta cell function, outperforming existing treatments like pioglitazone. The company plans to file an IND for BMF-219 in type 2 diabetes by late 2022, highlighting its potential as a long-acting, disease-modifying therapy for diabetes.
Biomea Fusion (Nasdaq: BMEA) presented new preclinical data on BMF-219, a covalent menin inhibitor, at the EASD Annual Meeting in Stockholm, demonstrating its ability to improve pancreatic beta cell function and glycemic control in a diabetic rat model. Over 4 weeks, BMF-219 significantly reduced HbA1c by 3.5% compared to liraglutide's 1.7%, along with improvements in fasting glucose and weight loss. The company aims to file an IND for BMF-219 in Type 2 Diabetes by late 2022, showcasing its potential as a disease-modifying oral treatment.
Biomea Fusion presented significant findings at the 19th International Myeloma Society Annual Meeting (August 25-27, 2022). BMF-219 demonstrated robust anti-tumor activity, achieving over 90% inhibition in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). The ongoing Phase I clinical trial, COVALENT-101, aims to explore BMF-219’s effects on patients with relapsed/refractory cancers. The preclinical results underscore BMF-219’s potential as a first-in-class menin inhibitor, indicating a promising future for its clinical applications.
Biomea Fusion (Nasdaq: BMEA) reported significant advancements in its clinical pipeline, focusing on BMF-219, a covalent menin inhibitor. The COVALENT-101 Phase I study is enrolling patients for various malignancies, with IND submissions for solid tumors and type 2 diabetes expected soon. Financial results show a net loss of $33.6 million for H1 2022, up from $14.3 million in H1 2021, primarily due to increased R&D expenses. Cash reserves stand at $150.2 million, down from $175.7 million at year-end 2021, indicating ongoing investment in product development and operational expansion.
Biomea Fusion (BMEA) announced significant findings from two oral presentations at the EASD Annual Meeting, showcasing its drug BMF-219. The preclinical studies reveal that BMF-219, a covalent menin inhibitor, achieves a 50% reduction in blood glucose levels and a notable 3.5% reduction in HbA1C, surpassing existing treatments like liraglutide. This novel treatment maintains glycemic control even after treatment cessation. The company plans to initiate a Phase I/II clinical trial in the second half of 2022, pending IND submission and clearance.
Biomea Fusion announced the first patient dosing in its Phase I clinical trial, COVALENT-101, evaluating BMF-219, a covalent menin inhibitor, for relapsed/refractory multiple myeloma (MM). This marks BMF-219 as the first menin inhibitor targeting MM. The trial has expanded to include cohorts for both MM and diffuse large B-cell lymphoma (DLBCL), while patient enrollment continues for acute leukemia cohorts. Approximately 35,000 new MM cases are diagnosed annually in the U.S., with a notably low 5-year survival rate of ~56% for affected patients.
Biomea Fusion has reported promising preclinical results for BMF-219, a covalent menin inhibitor, showcasing its potential in treating type 2 diabetes. In studies involving ZDF and STZ rat models, BMF-219 demonstrated significant improvements in glycemic control and reduced HbA1c levels, outperforming standard treatments like pioglitazone and liraglutide.
The company plans to initiate a Phase I/II clinical trial in the second half of 2022, contingent on IND submission and clearance, aiming to explore BMF-219's long-term efficacy in diabetes management.
Biomea Fusion, a clinical-stage biopharmaceutical company (Nasdaq: BMEA), announced CEO Thomas Butler's participation in the Jefferies Healthcare Conference on June 8, 2022, at 2:30 PM ET. The event will feature a fireside chat where Butler will discuss the company's innovative approach to developing covalent small molecules aimed at treating genetically defined cancers and metabolic diseases. A live webcast of the chat will be available for 90 days post-event at Biomea Fusion Investors.